Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2012

View Archived Issues

Bayer presents promising results from phase III studies of riociguat

Enlivex's lead product protects against GVHD in bone marrow transplantation

SP-333 demonstrates efficacy as treatment for gastrointestinal diseases

Bayer Schering Pharma prepares new agents for cancer

French group discloses novel agents for bone cancer

Novel potassium channel blockers presented by Xention

Swiss and German scientists synthesize new S1P receptor agonists

SJT Molecular Research divulges new agents for metabolic syndrome

Ares Trading discloses novel chemokine receptor ligands

Fujifilm Kyowa Kirin Biologics plans to develop bevacizumab biosimilar

SymBio completes recruitment in Japanese phase II study of antiemetic patch

COLTHERES consortium reports novel approaches to colon cancer therapy

Sosei confirms MAA filing of COPD treatment

New IL-1 receptor antagonist may ameliorate intestinal inflammation

Eisai signs agreement with Brazilian health agency for malaria and neglected tropical diseases

DepoVax found to enhance effect of investigational cocaine vaccine

Ezose enters collaboration to discover diagnostic biomarkers for multiple sclerosis

Qiagen and Bayer to collaborate on companion diagnostics for targeted anticancer therapies

Durata Therapeutics achieves milestone in phase III DISCOVER 2 trial

Prodrug formulated to deliver simvastatin to skeletal tissue

Biotecnol and PolyTherics to develop Tribody antibody drug conjugates

ZIOPHARM Oncology advances Ad-RTS-IL-12 to phase II

United Therapeutics receives complete response letter for oral treprostinil

FDA accepts NDA filing for controlled-release misoprostol vaginal insert

Biken and Mitsubishi Tanabe set to launch Tetrabik in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...